search icon
      blog search icon

      What Led The AVEO Pharmaceuticals Stock To Increase After-Hours? - Stocks Telegraph

      By Fahim Awan

      Published on

      March 14, 2022

      8:29 AM UTC

      What Led The AVEO Pharmaceuticals Stock To Increase After-Hours? - Stocks Telegraph

      At last check in after-hours trading, shares of AVEO Pharmaceuticals Inc. (AVEO) were up 8.47% at $4.10. AVEO Pharmaceuticals (AVEO) stock closed the last session at $3.78, decreasing -4.55% or -$0.18. Shares of the company fluctuated between $3.78 and $4.10 throughout the day. The number of shares exchanged was 0.17 million, less than the company’s 50-day daily volume of 0.31 million and lower than its Year to date volume of 0.31 million.

      In the past 12 months, AVEO Pharmaceuticals (AVEO) stock has advanced -69.61%, and in the last week, the stock has moved up 16.67%. For the last six months, the stock has lost a total of -43.07%, and over the last three months, the stock has decreased by -32.62%. The stock has returned -19.40% so far this year. AVEO stock is surging before the release of its quarterly results.

      How will AVEO Pharmaceuticals release its financial statements?

      AVEO Pharmaceuticals (AVEO) is a business stage, oncology-centered biopharmaceutical organization focused on conveying drugs that give a superior life to patients with the disease. AVEO presently showcases FOTIVDA (tivozanib) in the U.S. for the treatment of grown-up patients with backslid or recalcitrant progressed renal cell carcinoma (RCC) following at least two earlier fundamental treatments. AVEO keeps on creating FOTIVDA in immuno-oncology and other novel designated mixes in RCC and different signs and has other investigational programs in clinical turn of events.

      AVEO Pharmaceuticals (AVEO) is set to report full-year 2021 financial results today.

      • AVEO’s supervisory group will have a phone call and sound webcast at 8:30 a.m. ET on Monday, March 14, 2022, to examine the monetary outcomes and give a business update.
      • Admittance to the live webcast, or the ensuing filed recording, will be made accessible at the Calendar of Events sub-area inside the Investors segment of the AVEO.

      AVO’s recent collaboration

      • AVEO as of late gone into research coordinated effort with Actinium Pharmaceuticals, a forerunner in the advancement of designated radiotherapies.
      • AVEO teamed up to create and concentrate on a first-in-class immunizer radio-form (ARC) focusing on ErbB3, otherwise called HER3.
      • Actinium will use its AWE innovation stage and broad radiotherapy skill to form one of AVEO’s ErbB3 designated antibodies, with the strong alpha-transmitting radioisotope Actinium-225 (Ac-225).

      How AVEO will use the cooperation?

      AVEO Pharmaceuticals (AVEO) is zeroing in on the commercialization of FOTIVDA in cutting-edge RCC, which drove it to that cooperation with Actinium with an end goal to use its high-fondness counteracting agent program to grow its strong portfolio with a potential first-in-class designated radiotherapy. Through this AVEO will actually want to progress ErbB3 designated compound which is communicated in different strong cancers and is the third in the group of clinically approved ErbB targets.

      More From Stocks telegraph